Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial - Berger, Anne Katrin; Haag, Georg Martin; Grüllich, Carsten; Dietrich, Mareike; Apostolidis, Leonidas; Giesel, Frederik L.; Weber, Tim; Haberkorn, Uwe; Jäger, Dirk (British journal of cancer, 2018)
Gesehen am 06.05.2019